Given that sorafenib is the first-line systemic therapy in HCC at a later stage, it is imperative to investigate whether the sensitivity of sorafenib could be enhanced by YAP/TAZ inhibition depending on YAP/TAZ expression levels. This evidence concerns the gene WWTR1 and hepatocellular carcinoma.